Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Bone Marrow Transplantation

Volumn 20, Issue 7, 1997, Pages 553-560

  Van Rhee, F ^a   Szydlo, R M ^b   Hermans, J ^b   Devergie, A ^b   Frassoni, F ^b   Arcese, W ^b   De Witte, T ^b   Kolb, H J ^b   Niederwiser, D ^b   Jacobsen, N ^b   Gahrton, G ^b   Bandini, G ^b   Carreras, E ^b   Bacigalupo, A ^b   Michallet, M ^b   Ruutu, T ^b   Reiffers, J ^b   Goldman, J M ^b   Apperley, J ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

BMT; CML; Long term outcome

Indexed keywords

BCR ABL PROTEIN; CYCLOSPORIN A; METHOTREXATE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; KIDNEY DONOR; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0030707663     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700933     Document Type: Article

References (25)

1. Clift RA, Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-1956.
2. Marks DI, Hughes TP, Szydlo R et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia: influence of GVHD prophylaxis on outcome. Br J Haemarol 1992; 81: 383-390.
3. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1991; 75: 555-562.
4. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia: increased risk for relapse associated with T cell depletion. Ann Intern Med 1988; 108: 806-814.
5. Kolb HJ, Mittermuller J, Clemm Ch et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 762: 2462-2465.
6. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T cell dose. Blood 1993; 82: 2310-2318.
7. van Rhee F, Feng, L, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematological relapse. Blood 1994; 83: 3377-3383.
8. Gratwohl A, Hermans J, Niederwieser D et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant 1993; 12: 509-516.
9. Thomas ED, Storb R, Clift R et al. Bone marrow transplantation. New Engl J Med 1975; 292: 895-902.
10. Shulman HM, Sullivan KM, Weiden P et al. Chronic graft-versus-host disease syndrome in man. A long-term clinico-pathological study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
11. Cross NCP, Hughes TP, Lin F et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993; 84: 67-74.
12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1976; 53: 457-481.
13. Goldman JM, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia. New Engl J Med 1986; 314: 202-207.
14. Thomas ED, Clift RA, Feter A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
15. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
16. Hehlmann R, Heimpel H, Hasford J et al and the German CML Study Group. Randomised comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.
17. Allan NC, Richards SM, Shepherd PCA on behalf of the Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Survival benefit from interferon-alpha-n-1 is not confined to patients with cytogenetic response: results of a United Kingdom Medical Research Council randomised trial in chronic myeloid leukemia. Lancet 1995; 345: 1392-1397.
18. Lee MS, Kantarjian H, Talpaz M et al. Detection of minimal residual disease in Ph-positive chronic myelogenous leukemia following interferon therapy. Blood 1992; 79: 1920-1923.
19. Opalka B, Wandl UB, Becher R et al. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon-gamma. Blood 1991; 78: 2188-2193.
20. Hochhaus A, Lin F, Reiter A et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 1995; 91: 126-131.
21. Goldman JM; Szydlo R, Horowitz MM et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82: 2235-2238.
22. Enright H, Davies SM, DeFor T et al. Relapse after non-T cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukaemia: early transplantation, use of an unrelated donor and chronic graft-versus-host disease are protective. Blood 1996; 88: 714-720.
23. van Rhee F, Lin F, Cross NCP et al. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 1994; 14: 609-612.
24. Biernaux C, Loos M, Sels A et al. Detection of a major bcrabl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118-3122.
25. SJ Forman, JA Zaia. Review: treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 1994; 83: 2392-2398.